Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection

What Was Tested

The paper reports a study of Adrenomedullin, published as an observational study.

Bacterial infections such as febrile urinary tract infection (fUTI) may run a complicated course that is difficult to foretell on clinical evaluation only.

The researchers conducted a prospective multicentre cohort study including consecutive patients with f UTI at 35 primary-care centres and eight emergency departments.

Who Took Part

According to the abstract, 494 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Because the conventional biomarkers erythrocyte sedimentation rate (ESR), leucocyte count, C-reactive protein (CRP) and procalcitonin (PCT) have a limited role in the prediction of a complicated course of disease, a new biomarker-plasma midregional pro-adrenomedullin (MR-proADM)-was evaluated in patients with f UTI.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Adrenomedullin study over different clinics and patient groups.

Clinical and microbiological data were collected and plasma biomarker levels were measured at presentation to the physician.

What Was Measured

Bacterial infections such as febrile urinary tract infection (fUTI) may run a complicated course that is difficult to foretell on clinical evaluation only.

The researchers conducted a prospective multicentre cohort study including consecutive patients with f UTI at 35 primary-care centres and eight emergency departments.

The subject headings attached to it are Adrenomedullin, Biomarkers, C-Reactive Protein, Calcitonin, Calcitonin Gene-Related Peptide, Fever and Prognosis.

Author keywords: erythrocyte sedimentation rate, leucocyte count, pro-adrenomedullin, procalcitonin, pyelonephritis and urinary tract infection.

What This Means in Plain Language

The paper is a multicenter study of Adrenomedullin in 494 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2014 (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases), a journal based in England.

More context: the Adrenomedullin compound page, all human trials.